

## BY E-MAIL

February 24, 2022

BSE Ltd.

Phiroze Jeejeebhoy Towers 27<sup>th</sup> Floor, Dalal Street Mumbai 400 023

E-mail: corp.relations@bseindia.com

The National Stock Exchange of India Ltd.

Exchange Plaza, 5<sup>th</sup> Flr, Plot # C/1 G Block, Bandra-Kurla Complex, Bandra (E), Mumbai 400 051.

E-mail: takeover@nse.co.in

Dear Sir,

Re: <u>Declaration under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers)</u> Regulations, 2011

Pursuant to Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, we are enclosing herewith our disclosure for acquisition by the Company of 781 equity shares of Rs.10/- each of M/s. Lyka Labs Ltd. (Scrip Code: 500259) tendered in the open offer made to the public shareholders of the said company by us pursuant to Regulations 3(1) and 4 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Kindly acknowledge the receipt.

Thanking you

Yours faithfully

For and on behalf Ipca Laboratories Limited

Harish P. Kamath Company Secretary

Encl: a/a

Cc: Lyka Labs Ltd.

4801/B & 4802/A, GIDC Industrial Estate,

Ankleshwar – 393 002, Gujarat

E-mail id: companysecretary@lykalabs.com



## Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

## Part A - Details of Acquisition

Name of the Target Company (TC)	Lyka Labs Limit	ted		
Name of the Target Company (TC)  Name(s) of the acquirer and Persons Acting in Concert (PAC) with the Acquirer  Whether the acquirer belongs to Promoter / Promoter Group  Name(s) of the Stock Exchange(s) where the	Lyka Labs Limited  Acquirer Ipca Laboratories Limited Person Acting in Concert Mr. Pranay Godha Mrs. Neetu Godha Mrs. Usha Godha Mrs. Bhawna Godha Mrs. Bhawna Godha Mr. Premchand Godha Yes. Upon completion of open offer formalities under SEBI (SAST) Regulations  BSE Ltd. (BSE); and			
shares of TC are listed	The National Stock Exchange of India Ltd. (NSE)			
Details of the acquisition as follows	Number	% w.r.t total share / voting capital wherever applicable (*)	% w.r.t. total diluted share / voting capital of the TC (**)	
Before the acquisition under consideration, holding of acquirer along with PACs of:				
a. Shares carrying voting rights				
i. Ipca Laboratories Ltd.	76,24,142	26.57%	26.57%	
ii. Mr. Pranay Godha	3,00,000	1.05%	1.05%	
iii. Mrs. Neetu Godha	10,000	0.03%	0.03%	
iv. Mrs. Usha Godha	10,686	0.04%	0.04%	
v. Mrs. Bhawna Godha	6,000	0.02%	0.02%	
vi. Mr. Premchand Godha	10,900	0.04%	0.04%	
TOTAL	79,61,728	27.75%	27.75%	
b. Shares in the nature of encumberance (pledge/lien/non-disposal undertaking/others)	Nil	Nil	Nil	
c. Voting rights (VR) otherwise than by equity shares	Nil	Nil	Nil	
d. Warrants / convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	Nil	Nil	Nil	
e. Total (a+b+c+d)	79,61,728	27.75%	27.75%	

Ipca Laboratories Ltd. www.ipca.com

E: ipca@ipca.com CIN: L24239MH1949PLC007837



			. • A
Details of Acquisition / Sale			
a. Shares carrying voting rights acquired			
i. Ipca Laboratories Ltd.	781	0.001%	0.001%
b. VRs acquired otherwise than by equity shares	Nil	Nil	Nil
c. Warrants / Convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired		Nil	Nil
d. Shares in the nature of encumberance (pledge/lien/non-disposal undertaking/others)	Nil	Nil	Nil
e. Total $(a+b+c+/-d)$	781	0.001%	0.001%
After the acquisition, holding of		<u> </u>	
a. Shares carrying voting rights			
i. Ipca Laboratories Ltd.	76,24,923	26.58%	26.58%
ii. Mr. Pranay Godha	3,00,000	1.05%	1.05%
iii. Mrs. Neetu Godha	10,000	0.03%	0.03%
iv. Mrs. Usha Godha	10,686	0.04%	0.04%
v. Mrs. Bhawna Godha	6,000	0.02%	0.02%
vi. Mr. Premchand Godha	10,900	0.04%	0.04%
TOTAL	79,62,509	27.76%	27.76%
b. VRs otherwise than by equity shares	Nil	Nil	Nil
c. Warrants / convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	Nil	Nil	Nil
d. Shares in the nature of encumberance (pledge/lien/non-disposal undertaking/others)	Nil	Nil	Nil
e. Total (a+b+c+d)	79,62,509	27.76%	27.76%
Mode of acquisition (eg. Open market / public issue/rights issue/preferential allotment/interse transfer etc.)	public sharehol	l under open offe ders of the TC po and 4 of SEBI ( 111	ursuant to
Date of acquisition of shares or date of receipt of intimation of allotment of shares/VR/warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC	made pursuant (SAST) Regula	te tendered under to Regulation 3(1 tions, 2011 for w n was made on 2	l) and 4 of SEBI hich payment

Ipca Laboratories Ltd. www.ipca.com



Equity share capital/total voting capital of the TC before the said acquisition	2,86,90,000	100%	100%
Equity share capital /total voting capital of the TC after the said acquisition	2,86,90,000	100%	100%
Total diluted share/voting capital of the TC after the said acquisition (considering balance outstanding convertible warrants).	2,86,90,000	100%	100%

Signature of the acquirer / Authorised Signatory:

For Ipca Laboratories Lt

Harish P. Kamath Company Secretary

Place: Mumbai

Date: 24th February, 2022